Skin condition prevalence high, awareness low


Thursday, 17 January, 2019


Skin condition prevalence high, awareness low

A new Australian prevalence study1 of hidradenitis suppurativa (HS) estimates a very high number of Australians have the devastating skin condition.

The study, published in PLOS ONE, also suggests not all clinicians are familiar with the disease, resulting in delays to diagnosis for many Australians.1

HS is a chronic skin condition characterised by inflamed areas typically located around the armpits and groin.2,3 Also known in the past as ‘acne inversa’, HS can take on a variety of forms which can differ from person to person. HS can occur at any age, but the condition most commonly develops in adults in their early 20s.3

Based on face-to-face household interviews of a large (n=11,433) representative sample of the adult Australian population using a previously validated HS screening questionnaire, the robust and rigorous study estimates the prevalence of HS is 0.67% (approximately 165,000 Australians, based on a total Australian population of 25 million people5).1

In the study, 88 individuals were identified as potentially having HS. But only 6 (6.8%) had been previously diagnosed with HS.1 Many diagnosed and undiagnosed individuals had seen several clinicians/specialists regarding their condition.1

A quarter of the undiagnosed individuals suspected of having HS had not seen any clinician regarding their boils.1 In addition, many diagnosed and undiagnosed individuals had seen several clinicians/specialists regarding their condition.1 Therefore, the study speculates that the low diagnosis rate may result from a combination of factors, including:

  • decentralisation of care,
  • lack of familiarity of some clinicians with the disease, and
  • many patients not seeking medical help for single or infrequently recurring boils.1 The study’s conclusion indicates a need to increase awareness of the disease in Australia among both the broader medical community and the general population.1
     

Due to the severe impact that HS has on patients, this study is particularly important to understand the prevalence and diagnosis rates of HS in Australia, as well as the profile and characteristics of people living with HS and their management pathways. In a wide range of countries, the mean time between symptom onset and HS diagnosis is 7.2 years,4 which further illustrates why greater awareness and understanding of the condition is needed among healthcare professionals.

   Key findings:

  • Estimated prevalence of HS in Australia = 0.67% (or approx. 165,000 Australians)
  • Current diagnosis rate of suspected HS cases = 6.8%
  • 96.7% of undiagnosed individuals had previously talked to a GP about their condition
  • Individuals suspected of having HS were more likely to be female, young and obese
     
References
  1. Calao, M., Wilson, J., Spelman, L., Billot, L., Rubel, D., Watts, A. and Jemec, G. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PLOS ONE. 2018; 13(7)
  2. Mayo Health Clinic. Hidradenitis Suppurativa. Available at: http://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/home/ovc-20200012. Accessed May 2018
  3. Jemec G. Hidradenitis Suppurativa. N Engl J Med. 2012; 366:158-64
  4. Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015; 173(6):1546–9
  5. Australian Bureau of Statistics. Population Clock. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Web+Pages/Population+Clock?opendocument

Image credit: ©stock.adobe.com/au/yuriyzhuravov

Related News

Skipping meals increases risk for heart attack survivors

Heart attack survivors who skip breakfast or eat dinner close to bedtime are four to five times...

<40% of pregnant women getting flu vax

Women born overseas, those who smoke during pregnancy and those of Aboriginal and Torres Strait...

New epileptic seizure treatment for kids to impact globally

A new treatment for severe epileptic seizures in children will halve the number of kids being...


  • All content Copyright © 2019 Westwick-Farrow Pty Ltd